N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective

Introduction: SiRNA molecules with a feature of good gene-silencing are critical for drug discovery and development based on RNA interference. GalNAc-RNA therapeutics is a rapid growing area in RNA therapeutics.Areas covered: This article provides patent landscape and modification feature of GalNAc-RNA therapeutics. The US-granted patents from January 2004 to April 2023 were retrieved and analyzed.Expert opinion: Globally, our study is the first one to holistically depict a map of modifications and therapeutic applications for GalNAc-RNA therapeutics by patent data analysis. The results showed there were 8 major modifications and 5 new emerged modifications for GalNAc-RNA therapeutic agents. Especially, the study provides recent new emerged modifications in sugar, base, and internucleotide linkage of GalNAc-RNA therapeutic agents, e.g. morpholino-type ring, 5-methylcytosine, and phosphorodithioates. In addition, our study systematically demonstrated major therapeutic applications for GalNAc-RNA therapeutics, including liver or gallbladder disorders, anticancer, antihyperlipidemics, and disorders of the nervous system etc.

Automated summary

This article presents a patent landscape and modification features of GalNAc-RNA therapeutics. The study is the first to provide a comprehensive analysis of modifications and therapeutic applications of GalNAc-RNA therapeutics through patent data analysis. The results reveal the existence of 8 major modifications and 5 newly emerged modifications for GalNAc-RNA therapeutic agents. Additionally, the study highlights recent modifications in sugar, base, and internucleotide linkage of GalNAc-RNA therapeutic agents, such as morpholino-type ring, 5-methylcytosine, and phosphorodithioates. Furthermore, the study demonstrates major therapeutic applications of GalNAc-RNA therapeutics, including liver or gallbladder disorders, anticancer treatments, antihyperlipidemics, and nervous system disorders.